Showing results (151-160 of 182) with videos related to
Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trialM H Kulke, P Ruszniewski, E Van Cutsem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJames C Yao, Catherine Lombard-Bohas, Eric Baudin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET)Kimberly J Perez, Nora Horick, Joanna Baginska, et al.Pancreas|April 18, 2013
Consensus guidelines for the management and treatment of neuroendocrine tumorsPamela L Kunz, Diane Reidy-Lagunes, Lowell B Anthony, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Cancer Susceptibility Gene Mutations in Individuals With Colorectal CancerMatthew B Yurgelun, Matthew H Kulke, Charles S Fuchs, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitusChen Yuan, Douglas A Rubinson, Zhi Rong Qian, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasEunice L Kwak, Janusz Jankowski, Sarah P Thayer, et al.Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.The American Journal of Surgical Pathology|February 2, 2010
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data setDavid S Klimstra, Irvin R Modlin, N Volkan Adsay, et al.Pancreas|September 14, 2016
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine TumorsZhi Rong Qian, Tingting Li, Monica Ter-Minassian, et al.Pageof 19